**Abstract**

**Objectives:** There is considerable evidence that disturbances in neurotransmitter systems contribute to the pathophysiology of depression. Brain-derived neurotrophic factor (BDNF) is involved in the pathophysiology of depression, and in the mechanism of action of antidepressant medications. The mature form of BDNF is derived from proBDNF through tissue type plasminogen activator (tPA) and the plasminogen system in the brain. Therefore, tPA might be involved in the development of major depressive disorder (MDD) and its response to antidepressant treatment. Mirtazapine acts as an antagonist of the adrenergic alpha 1, 2 and serotonin receptors. The present study determined the relationship between the Alu insertion/deletion (I/D) polymorphism on the tPA gene and the clinical outcome of mirtazapine treatment in 422 Korean MDD patients.

**Methods:** 422 patients were enrolled in this study, and symptoms were evaluated by 21-item Hamilton Depression Rating scale. After 1, 2, 4, and 8 weeks of mirtazapine treatment, the association between Alu I/D polymorphism on tPA gene and remission/response outcomes were evaluated.

**Results:** The proportion of I/I homozygote in responders was higher than that in non-responders, whereas the proportion of D/D homozygote in responders was lower than that in non-responders at 8 weeks of treatment (P=0.032, OR=1.57). The percent decline of HAMD-21 score in I allele carriers was larger than that of D allele homozygotes at 2 and 8 weeks after mirtazapine treatment (P=0.035 and 0.007, respectively). I allele carriers were also significantly associated with remission at 8 weeks of treatment (P=0.047, OR=2.2).

**Conclusions:** These results show that treatment response and remission to mirtazapine were significantly associated with Alu insertion/deletion polymorphism of the tPA gene. This suggests that Alu insertion/deletion polymorphism affects the therapeutic action of mirtazapine in MDD, and may be a potential genetic marker for the prediction of therapeutic response to mirtazapine treatment in patients with MDD.
